U.S. Markets closed

Daxor Corporation Announces the Sale of a BVA-100 Blood Volume Analyzer to Banner Good Samaritan Medical Center of Phoenix, Arizona

NEW YORK, NY--(Marketwire - Mar 7, 2013) - Daxor Corporation ( NYSE MKT : DXR ), an investment company with medical instrumentation and biotechnology operations, announced today that Banner Good Samaritan Medical Center of Phoenix, Arizona has purchased a BVA-100 Blood Volume Analyzer.

Banner Good Samaritan Medical Center is a 668-bed facility which opened in 1911. The Hospital is a Level One trauma center providing emergency services and advanced heart and cardiovascular care and is well known for being a top teaching hospital for future physicians. The Banner Good Samaritan Transplant Center is the oldest in Arizona. The medical professionals in their transplant center are the most experienced in the state and they provide care to patients requiring a kidney, liver, pancreas or kidney/pancreas transplant. 

In 1969, the first organ transplant in Arizona was performed at Banner Good Samaritan. More than 3,200 kidney transplants have been performed there and the Hospital is one of the largest providers of kidney transplants in Arizona. In 2011, Banner Good Samaritan was ranked as the number one kidney transplant center in the United States.

The Cavanaugh Heart Center at Banner Good Samaritan Medical Center is a leader in technologically advanced treatments such as the Left Ventricular Assist Device (LVAD) for heart patients who have run out of basic treatment options. The Banner Good Samaritan Stroke Center treats patients with diseases, disorders and injuries of the brain, spine and nervous system. Dr. Gamal Sidarous of Banner Medical Center said the following: "We are excited to have acquired the blood volume analyzer. We see this as a valuable tool for guiding therapy for our heart failure patients."

Dr. Joseph Feldschuh, the President of Daxor, is a cardiologist and he stated: "Banner Good Samaritan is a Level One trauma center. This is the highest designation a hospital can attain for treating trauma patients. There have been multiple published studies involving the BVA-100 Blood Volume Analyzer which have documented the difficulties that experienced physicians have in determining the blood volume status of a patient using indirect measurements. The ability to accurately measure a patient's blood volume status enables physicians to treat patients more precisely with respect to the administration of transfusions, withholding of transfusions and administering the appropriate amount of resuscitation fluids." 

Daxor Corporation manufactures and markets the BVA-100 Blood Volume Analyzer, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at www.Daxor.com.